The Board of Jagsonpal Pharmaceuticals at its meeting held on 12 March 2026 approved a proposal to buyback up to 16,00,000 fully paid-up equity shares of the company at a price of Rs 250 per equity shares (a premium of through Tender Offer method, subject to shareholders approval. This represents 2.4% of the total equity shares of the Company and 7.3% of the non-promoter shareholding of the company. The proposed buyback will be undertaken for an aggregate amount not exceeding Rs 40 crore, representing ~18.4% of the company`s total paid-up equity share capital and free reserves based on the latest audited financial statements as of 31 March 2025. Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 March 2026.Powered by Capital Market - Live News

Net profit of Jagsonpal Pharmaceuticals declined 65.77% to Rs 10.95 crore in the quarter ended December 2025 as against Rs 31.99 crore during the previous quarter ended December 2024. Sales declined 1.46% to Rs 72.95 crore in the quarter ended December 2025 as against Rs 74.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales72.9574.03 -1 OPM %22.3021.38 - PBDT18.9917.90 6 PBT16.6015.49 7 NP10.9531.99 -66 Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 21 January 2026.Powered by Capital Market - Live News

Jagsonpal Pharmaceuticals has allotted 56,571 equity shares under ESOP on 18 November 2025. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,34,49,398 (constituting of 6,67,24,699 equity shares of Rs. 2/- each) to Rs. 13,35,62,540 (constituting of 6,67,81,270 equity shares of Rs. 2/- each).Powered by Capital Market - Live News